Innate Pharma Files 6-K Report

Ticker: IPHA · Form: 6-K · Filed: Apr 2, 2026 · CIK: 0001598599

Sentiment: neutral

Topics: regulatory-filing, foreign-issuer

TL;DR

Innate Pharma filed a 6-K on 4/2/26. Standard reporting.

AI Summary

Innate Pharma SA filed a 6-K report on April 2, 2026. The filing includes exhibit EX-99.1 and a complete submission text file. The company's mailing and business address is in Marseille, France.

Why It Matters

This filing indicates ongoing regulatory compliance and reporting for Innate Pharma SA, a company involved in biological products.

Risk Assessment

Risk Level: low — This is a routine foreign issuer report (6-K) and does not contain specific financial or operational news that would indicate elevated risk.

Key Players & Entities

FAQ

What type of report is Innate Pharma SA filing?

Innate Pharma SA is filing a Form 6-K, which is a Report of foreign issuer.

When was this 6-K filing accepted by the SEC?

The filing was accepted on April 2, 2026.

What is the CIK number for Innate Pharma SA?

The CIK number for Innate Pharma SA is 0001598599.

Where is Innate Pharma SA located?

Innate Pharma SA's mailing and business address is 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE.

What is the SIC code associated with Innate Pharma SA?

The SIC code is 2836, which corresponds to Biological Products, (No Diagnostic Substances).

Filing Stats: 159 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2026-04-02 06:01:47

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date April 2, 2026 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing